White Paper
Mediteanox® and Pomanox®: Cardiovascular Health evidence
![Mediteanox® and Pomanox®: Cardiovascular Health evidence](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_product_file/publications/food-beverage-nutrition/nutraingredients-usa.com/product-innovations/mediteanox-r-and-pomanox-r-cardiovascular-health-evidence/9486763-1-eng-GB/Mediteanox-R-and-Pomanox-R-Cardiovascular-Health-evidence.jpg)
A Spanish Government-supported 20 week clinical trial investigated properties of heart-friendly Mediterranean diet olive and pomegranate polyphenols (Mediteanox® and Pomanox®) on early atherosclerosis markers in 67 seemingly healthy participants.
From the results of the authoritative study, Dr Quirós-Fernández and co-authors conclude that standardized amounts of polyphenols as Pomanox® and Mediteanox®, improved endothelial function, blood pressure and circulating oxLDL, especially in subjects with altered parameters.
According to the authors, regular intake may help reduce cardiovascular risk.